RxDoctor Payments Data

Morgan Poncy, MD

Internal Medicine · Jupiter, FLNPI 1891716056

Payments from drug & device makers

$1,964in general payments, 2019–2025

Across 119 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$461
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$230
  • Amgen$189
  • Microport Orthopedics Inc$188
  • Novartis$163
  • AbbVie$130
  • plus $603 from 15 others

What the payments were for

  • Food & beverage$1,958100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,964 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$157,664
Medicare patients
402
Services billed
3,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide162$186,926
EliquisApixaban70$108,446
OzempicSemaglutide82$99,503
XareltoRivaroxaban62$77,486
Repatha SureclickEvolocumab61$69,205
Dupixent PenDupilumab13$56,975
Repatha SyringeEvolocumab39$33,836
GenotropinSomatropin24$28,574
EntrestoSacubitril/Valsartan18$19,318
Rosuvastatin Calcium609$11,899
SynthroidLevothyroxine Sodium52$5,829
Olmesartan Medoxomil139$4,481
Desvenlafaxine Succinate ErDesvenlafaxine Succinate25$3,763
Levothyroxine Sodium239$3,730
Metoprolol Succinate168$3,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$55$186,926162 claims
PfizerEliquis, Genotropin, Paxlovid$109$138,449138 claims
Novo NordiskOzempic$461$99,50382 claims
NovartisEntresto$163$19,31818 claims
AbbVieSynthroid$130$5,82952 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →